EDITAS MEDICINE, INC. Deferred Tax Assets, Tax Credit Carryforwards
EDITAS MEDICINE, INC. (EDIT) had Deferred Tax Assets, Tax Credit Carryforwards of $35.95 million as of 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Credit Carryforwards
us-gaap:DeferredTaxAssetsTaxCreditCarryforwards · last filed 2026-03-09
- 2025-12-31: Deferred Tax Assets, Tax Credit Carryforwards $35.95M.
- 2024-12-31: Deferred Tax Assets, Tax Credit Carryforwards $31.77M.
- 2023-12-31: Deferred Tax Assets, Tax Credit Carryforwards $25.65M.
- 2022-12-31: Deferred Tax Assets, Tax Credit Carryforwards $20.08M.
| Period end | Deferred Tax Assets, Tax Credit Carryforwards |
|---|---|
| 2025-12-31 | $35.95M 10-K · filed 2026-03-09 |
| 2024-12-31 | $31.77M 10-K · filed 2026-03-09 |
| 2023-12-31 | $25.65M 10-K · filed 2025-03-05 |
| 2022-12-31 | $20.08M 10-K · filed 2024-02-28 |
| 2021-12-31 | $25.03M 10-K · filed 2023-02-22 |
| 2020-12-31 | $19.35M 10-K · filed 2022-02-24 |
| 2019-12-31 | $13.77M 10-K · filed 2021-02-26 |
| 2018-12-31 | $10.06M 10-K · filed 2020-02-26 |
| 2017-12-31 | $5.26M 10-K · filed 2019-03-01 |
| 2016-12-31 | $2.01M 10-K · filed 2018-03-08 |
| 2015-12-31 | $730.00K 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |